Comparison of Drug-Eluting Stents in Acute Myocardial Infarction Patients with Chronic Kidney Disease
暂无分享,去创建一个
Ju Han Kim | Kyung Hoon Cho | M. Jeong | Y. Ahn | Young Jo Kim | M. Cho | C. Kim | D. Sim | S. Chae | T. Hong | I. Seong | K. Seung | Seung‐Jung Park | S. Saito | Y. Jang | J. Bae | W. Chung | S. Rha | J. Kang | Y. Hong | S. Hur | D. Choi | Jong Hyun Kim | K. Park | Seung Hwan Hwang | Khurshid Ahmed | Daisuke Hachinohe | Ju Han Kim | M. Lee | M. Kim | K. Cho | D. Hachinohe | J. H. Kim
[1] Si‐Hyuck Kang,et al. Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction. , 2013, International journal of cardiology.
[2] Byung Ok Kim,et al. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[3] Doo Sun Sim,et al. Current management of acute myocardial infarction: experience from the Korea Acute Myocardial Infarction Registry. , 2010, Journal of cardiology.
[4] D. Kandzari. Development and performance of the zotarolimus-eluting Endeavor® coronary stent , 2010, Expert review of medical devices.
[5] M. Jeong,et al. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. , 2009, The American journal of cardiology.
[6] O. Muller,et al. Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses , 2008, Circulation. Cardiovascular interventions.
[7] Aloke V. Finn,et al. Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study , 2008, Circulation.
[8] Seung‐Jung Park,et al. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. , 2008, International journal of cardiology.
[9] R. Virmani,et al. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. , 2007, The American journal of cardiology.
[10] E. Camenzind,et al. Response to Letter Regarding Article, “Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern” , 2007 .
[11] William Wijns,et al. A Cause for Concern , 2007 .
[12] Neville Kukreja,et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.
[13] Barbara T. Unger,et al. Comparison of safety and efficacy of sirolimus-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction. , 2006, The American journal of cardiology.
[14] G. Stone,et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. , 2005, American heart journal.
[15] F. Eberli,et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.
[16] R. Ferrari,et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. , 2005, JAMA.
[17] Marco Valgimigli,et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. , 2005, Journal of the American College of Cardiology.
[18] A. Murray,et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. , 2005, Journal of the American Society of Nephrology : JASN.
[19] Robert M Califf,et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.
[20] P. Serruys,et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. , 2004, Journal of the American College of Cardiology.
[21] J. Boura,et al. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials , 2003, The Lancet.
[22] Ethan M Balk,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[23] G. Stone,et al. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[24] U. Deligonul. Coronary Morphologic andClinical Determinants ofProcedural OutcomeWith Angioplasty forMultivessel Coronary Disease Implications forPatient Selection , 1990 .
[25] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.
[26] C. Nam,et al. ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.4.323 Comparison of Sirolimus and Paclitaxel-Eluting Stents for , 2022 .